Related Experiment Video
Updated: Mar 9, 2026
07:58
Electrophysiological Methods to Assess Peripheral Pain Block in an Anesthetized Rat
Published on: November 21, 2025
233
Analgesic Microneedle Patch for Neuropathic Pain Therapy.
Xi Xie1,2, Conrado Pascual1,3, Christopher Lieu1
1AfaSci Research Laboratories , Redwood City, California 94063, United States.
ACS Nano
|December 22, 2016
Summary
Dissolvable microneedle patches painlessly deliver calcitonin gene related peptide (CGRP) antagonists for targeted neuropathic pain relief. This novel approach offers effective analgesia without motor or sensory side effects, unlike current treatments.
Area of Science:
- Pharmacology
- Neurology
- Biomaterials Science
Background:
- Neuropathic pain, often caused by nerve injury, is challenging to treat effectively.
- Current treatments for neuropathic pain have limited efficacy and significant side effects.
- Calcitonin gene-related peptide (CGRP) plays a key role in chronic neuropathic pain.
- Existing local anesthetics lack specificity, impacting both sensory and motor functions.
Purpose of the Study:
- To develop and evaluate an analgesic microneedle (AMN) patch for targeted, painless transdermal delivery of a CGRP antagonist peptide.
- To assess the efficacy and safety of AMN patches in treating localized neuropathic pain in rat models.
- To compare the AMN patch treatment with conventional therapies for neuropathic pain.
Main Methods:
- Development of dissolvable microneedles for transdermal drug delivery.
- Utilizing a selective CGRP antagonist peptide for targeted CGRP receptor blockade.
- Evaluation of analgesic effects in rat models of neuropathic pain (spared-nerve injury, diabetic neuropathy) and neurogenic inflammation (UVB radiation).
- Assessment of behavioral pain sensitivity to thermal and mechanical stimuli.
- Monitoring for motor function impairment, nociception changes, skin irritation, and systemic side effects.
Main Results:
- AMN patches effectively reduced pain sensitivity in various neuropathic pain models.
- The treatment demonstrated high specificity, targeting CGRP receptors without affecting normal nociception or motor function.
- No significant skin irritation or systemic adverse effects were observed.
- Analgesic effects were achieved painlessly via transdermal delivery.
Conclusions:
- Dissolvable microneedle patches offer a safe, effective, and simple method for managing localized neuropathic pain.
- Targeted delivery of CGRP antagonist peptides via microneedles presents a significant advantage over current treatment options.
- This approach holds promise for improved patient outcomes in neuropathic pain management.
